Compare UNB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | ADCT |
|---|---|---|
| Founded | 1891 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 136.1M |
| IPO Year | 1999 | 2019 |
| Metric | UNB | ADCT |
|---|---|---|
| Price | $23.78 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 4.6K | ★ 1.7M |
| Earning Date | 04-15-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.76% | N/A |
| EPS Growth | 25.52 | ★ 30.86 |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | $19.17 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $20.65 | $0.78 |
| 52 Week High | $26.54 | $4.98 |
| Indicator | UNB | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 50.72 | 61.38 |
| Support Level | $23.58 | $1.03 |
| Resistance Level | $24.49 | $1.45 |
| Average True Range (ATR) | 0.32 | 0.08 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 46.87 | 83.37 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).